Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) has announced that its product Mitiglinide is now to be officially reimbursed under the National Reimbursement Drug List ("NRDL") published by Ministry of Human Resources and Social Security today.
More info..

Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has announced its interim results for the six months ended 30 June 2016.
More info..

Uni-Bio Science Group Ltd (HKEx: 690) announced that it has signed a strategic alliance agreement with China Resources Zizhu Pharmaceutical Co., Ltd.
More info..

Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has announced its audited annual results for the year ended 31 December 2015.
More info..

Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) today announced that its long-acting Human Erythropoietin-Fc fusion protein injection ("Uni-EPO-Fc") has successfully completed the single ascending dose tolerability study of the Phase I clinical trial.

More info..

Uni-Bio Science Group Limited ("Uni-Bio" or the "Group"; HKEx code: 690) today announced that it will acquire exclusive global rights to manufacture and commercialise mitiglinide, a new oral antidiabetic agent, from Jiangsu Hansoh Pharmaceutical Co. Ltd ("Hansoh").


More info..

Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) is pleased to announce that the Group's chemical manufacturing line in Beijing has successfully passed the inspection under "Good Manufacturing Practice (2010 revision)"("GMP 2010") and received the Certificate of GMP for pharmaceutical products issued by China Food and Drug Administration ("CFDA") on 17 August 2015.

More info..

Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) has announced its interim results for the six months ended 30 June 2015. Following the bolstering of the sales and marketing teams and the Medical Function last year
More info..

Uni-Bio Science Group Limited ("Uni-Bio" or the "Group";HKEx code: 690) today announced positive top-line results of the Phase III clinical trial which assessed the efficacy and safety of Uni-E4, Uni-Bio's proprietary recombinant GLP-1 receptor agonist for the treatment of Type-2 diabetes.
More info..

Uni-Bio Science Group Limited ("Uni-Bio" or the "Group";HKEx code: 690) has garnered the "Pharmaceuticals Award" for Best Innovation with its Uni-E4 project at the inaugural Hong Kong Business ("HKB") Listed Companies Awards. As the winner under the pharmaceuticals category, the accolade is a strong testimony for the innovation of Uni-Bio's Uni-E4, the Group's proprietary recombinant GLP-1 receptor agonist for the treatment of Type-2 diabetes.

More info..

Hong Kong Investor Relations Association (HKIRA) today announced the winners of its inaugural HKIRA 1st Investor Relations Awards. Guests from listed companies and the IR profession were present at today's IR Awards Conference and the Awards Presentation Ceremony to celebrate the winners' IR excellence and their dedication to IR best practice.
More info..

Uni-Bio Science Group Limited ("Uni-Bio" or the "Group";HKEx code: 690) has garnered the "Best IR Company - Small Cap" Award after passing the stringent polling process of Hong Kong Investor Relations Association's ("HKIRA") first Investor Relations Awards ("IR Awards").
More info..

Uni-Bio Science Group Limited ("Uni-Bio" or the "Group";HKEx code: 690) today announced that its New Drug Application ("NDA") for Uni-PTH, the Group's proprietary parathyroid hormone 1-34 analogue
More info..

Uni-Bio Science Group Limited ("Uni-Bio" or the "Group;" HKEx code: 0690) has announced its results for the nine months ended 31 December 2014 (the "Period"), subsequent to its announcement of changing the end date for its financial year from 31 March to 31 December earlier in 2014.
More info..

Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has announced its interim results for the six months ended 30 September 2014. Backed by a strong management team and guided by a clear development roadmap, the Group achieved solid growth as it continued to expand its core business and strengthened its business foundation through various initiatives during the period under review.

More info..

Uni-Bio Science Group Limited ("Uni-Bio" or the "Group;" HKEx code: 690) today announced that it has entered into a strategic alliance agreement with Samil Pharm Co., Limited
More info..

Uni-Bio Science Group Limited ("Uni-Bio" or the "Group;" HKEx code: 690) has achieved an outstanding performance during the financial year 2013/14. The Group's topline growth beat the industry average while its two new prescription drugs, Uni-E4 and Uni-PTH, both reached major clinical milestone of completing all required clinical trials.

More info..

Uni-Bio Science Group Limited ("Uni-Bio" or the "Group;" HKEx code: 690) today reports successful Phase III clinical trial results of Uni-PTH, a once-daily prescription new drug for osteoporosis.

More info..

Uni-Bio Science Group Limited ("Uni-Bio" or the "Group") (SEHK code: 690) strengthened the composition of the Board of Directors ("Board") and senior management team to enhance business fundamentals and to initiate new business development strategies.
More info..